The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008).
 
Naomi Kiyota
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Merck Serono; MSD; Ono Pharmaceutical
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Eisai; Merck Serono; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst)
 
Makoto Tahara
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Merck Serono; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Celgene; MSD; Ono Pharmaceutical; Pfizer; Rakuten Medical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Rakuten Medical (Inst)
 
Hirofumi Fujii
No Relationships to Disclose
 
Tomoko Yamazaki
Research Funding - AstraZeneca (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Hiroki Mitani
No Relationships to Disclose
 
Shigemichi Iwae
No Relationships to Disclose
 
Yasushi Fujimoto
No Relationships to Disclose
 
Yusuke Onozawa
Honoraria - Bayer
 
Nobuhiro Hanai
Honoraria - Bristol-Myers Squibb; Merck Serono; Ono Pharmaceutical
Research Funding - Chugai/Roche (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Rakuten Medical (Inst)
 
Takenori Ogawa
No Relationships to Disclose
 
Hiroki Hara
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Lilly; MSD; Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); LSK BioPharma (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Nobuya Monden
No Relationships to Disclose
 
Eiji Shimura
No Relationships to Disclose
 
Shujiro Minami
Speakers' Bureau - Cochlear
Research Funding - Taiho Pharmaceutical (Inst)
 
Takashi Fujii
No Relationships to Disclose
 
Kaoru Tanaka
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb; Eisai; Hisamitsu Pharmaceutical; Merck Serono; Merck Sharp & Dohme; Ono Pharmaceutical
 
Takeshi Kodaira
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Canon Medical System; Merck Serono; Ono pharmaceutical; Taiho Pharmaceutical
 
Junki Mizusawa
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Kenichi Nakamura
Honoraria - Bayer Yakuhin; Chugai Pharma
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyorin (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Ryuichi Hayashi
No Relationships to Disclose